HDAC3 AS A POTENTIAL THERAPEUTIC TARGET FOR LANGERHANS CELL HISTIOCYTOSIS

$532,000FY2024Defense Health AgencyDOD

Henry Ford Health System, Detroit MI

Investigators

View source on USAspending →